About
About Gufic Biosciences Limited
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
Visit company website
5 years, 6 months ago
Gufic Biosciences Limited is currently in a long term uptrend where the price is trading 46.7% above its 200 day moving average.
From a valuation standpoint, the stock is 54.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Gufic Biosciences Limited's total revenue rose by 47.7% to $1B since the same quarter in the previous year.
Its net income has increased by 87.8% to $132M since the same quarter in the previous year.
Finally, its free cash flow grew by 40.1% to $187M since the same quarter in the previous year.
Based on the above factors, Gufic Biosciences Limited gets an overall score of 5/5.